Lupin Q1 FY24 Growth Metrics and ESG Goals

Q1 FY24: Key Developments Significant positive momentum on all fronts Financials Sales and Adj. EBITDA* Margin Trajectory 40,912 42,446 43,303 36,040 Pipeline gTiotropium approved 47,421 Compliance 13.9% 14.4% 12.2% 10.6% US FDA 4.5% TGA Q1 FY23 FY23 Q2 Q3 Q4 Q1 FY23 FY23 FY24 Australia Sales EBITDA margin * excludes NCE, Fx and Other Income Other Agencies US FDA, TGA and Canada gDarunavir launched LUPIN With 180 day exclusivity Successful Nagpur OSD inspection Received EIR for Pithampur Unit-2 with Resolution of Warning letter Completed Nagpur Unit-2 and Mandideep Unit-1 inspections with no critical observations Successful inspections from Germany and other authorities 4

View entire presentation